The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...

Nucleoside reverse transcriptase translocation inhibitors (NRTTIs) are a novel class of antiretroviral agents that inhibit HIV replication by targeting the viral reverse transcriptase enzyme and ...

At the 12th International HIV Drug Resistance Workshop, held June 10-14, 2003, in Los Cabos, Mexico, investigators from around the world provided the latest results from studies of resistance topics ...

Scientists at Merck & Co. have unveiled the structure of the company’s latest candidate for HIV pre-exposure prophylaxis ...

Promega will license a novel engineered reverse transcriptase from Watchmaker Genomics to enhance accuracy and sensitivity in ...

† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...

Partnership delivers advanced reverse transcriptase technology to enhance sensitivity, robustness and reproducibility of molecular analysis in clinical, applied and pharmaceutical applications Promega ...

Alzheimer's disease is the most common cause of dementia and affects more than a tenth of Americans aged 65 and older. The disease has proven difficult to develop new treatments for, and available ...